Chinese biotech firm Immorna raises $100m in extended Series A rounds

Chinese biotech firm Immorna raises $100m in extended Series A rounds

Photo by National Cancer Institute on Unsplash

Immorna, a Chinese developer of mRNA-based therapeutics, has snapped up $100 million in Series A+ and A++ rounds in a bid to support the clinical development of its drug candidates, according to an announcement on Monday. 

Edited by: Padma Priya

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter